Navigation Links
Landmark Trial Provides Vital Information for Cardiac Disease Treatment
Date:2/18/2009

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.


About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson
Senior Director, Public Relations
NorthShore University HealthSystem
(847) 570-3146


###

Read the full story at http://www.prweb.com/releases/2009/02/prweb2114514.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. Landmark trial to evaluate cardioprotective properties of insulin
9. Safeway Inc. and the Prostate Cancer Foundation to Fund Landmark Prostate Cancer Research Collaboration
10. Yale launches landmark VIRGO study of young women with heart disease
11. Hospital Launches Landmark Project in Emergency Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Landmark Trial Provides Vital Information for Cardiac Disease Treatment
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: